^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    1d
    RENEW-IN: Allergy Delabeling in Antibiotic Stewardship - Intervention (clinicaltrials.gov)
    P4, N=3800, Recruiting, Abramson Cancer Center at Penn Medicine | Phase classification: P=N/A --> P4
    Phase classification
    1d
    FIL_LymDeCo: Neurocognitive Assessment in Long-Term Survivors of Lymphoma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New trial
    1d
    ROMA: Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=144, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide
    1d
    A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    Tazverik (tazemetostat)
    1d
    VISCOTHEM-2: Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia (clinicaltrials.gov)
    P=N/A, N=410, Not yet recruiting, Centre Hospitalier Annecy Genevois
    New trial
    1d
    CAREMM-011: CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    1d
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    1d
    Acalabrutinib in CNSL (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Apr 2026 --> Nov 2025
    Trial primary completion date
    |
    Calquence (acalabrutinib)
    1d
    MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=12, Recruiting, City of Hope Medical Center | Suspended --> Recruiting
    Enrollment open
    1d
    Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi. (PubMed, Blood Glob Hematol)
    TCR clonality was increased in EBV+ cHL, with trend towards further increase in clonality in HIV+. Through a multiomic approach of a well-characterized, HIV-inclusive cHL cohort from one of the most resource-limited countries in the world, we were able to recapitulate known, and identify novel molecular differences by HIV and EBV status.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    1d
    UBC9 silencing-mediated PPARα deSUMOylation induces inhibition of cell proliferation by ferroptosis in acute myeloid leukemia. (PubMed, Arch Med Sci)
    UBC9 silencing resulted in viability decrease, apoptosis and lipid peroxidation promotion, Fe2+ upregulation, and GPX4, SLC7A11, and PPARα downregulation in THP-1 cells, which were all counteracted by pirinixic acid. UBC9 silencing-induced PPARα deSUMOylation induces suppression of AML cell growth by ferroptosis.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • UBE2I (Ubiquitin Conjugating Enzyme E2 I)
    1d
    Comparison of the efficacy of vindesine and leurocristine for pediatric acute lymphoblastic leukemia and their effects on quality of life. (PubMed, Arch Med Sci)
    Group A showed no significant difference in the total efficacy rate and 5-year overall survival after treatment (p > 0.05) and had lower medical expenses, length of hospital stay, IL-6 and TNF-α expression, and total incidence of adverse reactions and higher KPS scores than group B (p < 0.05). Although no significant difference was observed between vindesine and leurocristine in treating pediatric acute lymphoblastic leukemia, patients administered vindesine had fewer adverse reactions, shorter length of hospital stay, lower medical expenses, and higher quality of life than those administered leurocristine, indicating a potential association with decreased serum IL-6 and TNF-α expression.
    Journal • HEOR
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    vincristine • vindesine